GRAFT POLYMER UK LS -001 (J4I) - Total Liabilities
Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has total liabilities worth €2.61 Million EUR (≈ $3.05 Million USD) as of May 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GRAFT POLYMER UK LS -001 (J4I) cash flow conversion to assess how effectively this company generates cash.
GRAFT POLYMER UK LS -001 - Total Liabilities Trend (2022–2025)
This chart illustrates how GRAFT POLYMER UK LS -001's total liabilities have evolved over time, based on quarterly financial data. See GRAFT POLYMER UK LS -001 (J4I) net assets for net asset value and shareholders' equity analysis.
GRAFT POLYMER UK LS -001 Competitors by Total Liabilities
The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KNOREX LTD.
NYSE MKT:KNRX
|
USA | $9.78 Million |
|
PPK Group Ltd
AU:PPK
|
Australia | AU$31.71 Million |
|
S-Energy Co.Ltd
KQ:095910
|
Korea | ₩161.54 Billion |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
Malaysia | RM37.63 Million |
|
TURA GROUP AB
F:8WO
|
Germany | €329.03 Million |
|
Secuve Co. Ltd
KQ:131090
|
Korea | ₩3.32 Billion |
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
USA | $1.72 Million |
|
White Energy Company Ltd
AU:WEC
|
Australia | AU$56.69 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down GRAFT POLYMER UK LS -001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GRAFT POLYMER UK LS -001 stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GRAFT POLYMER UK LS -001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GRAFT POLYMER UK LS -001 (2022–2025)
The table below shows the annual total liabilities of GRAFT POLYMER UK LS -001 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-05-31 | €119.00K ≈ $139.12K |
-70.83% |
| 2024-05-31 | €408.00K ≈ $476.99K |
+5.97% |
| 2023-05-31 | €385.00K ≈ $450.11K |
-83.39% |
| 2022-05-31 | €2.32 Million ≈ $2.71 Million |
-- |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more